Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announc
(Financial Post, 2025-10-24T11:31:34Z)